Wednesday, September 2, 2015

Knight Therapeutics to collaborate with Medison Biotech

Knight Therapeutics to collaborate with Medison Biotech

September 1, 2015 by · Leave a Comment 

Tweet Knight Therapeutics (TSX:GUD) and closely-held Medison Biotech (1995) Ltd. of Israel have entered a strategic collaboration to bring innovative treatments to patients in Canada, Israel and Romania. The companies will maintain a structure that will scan and evaluate the productive Israeli pharma/biotech/device landscape on a regular basis and will provide them with the required […]

Knight to commercialize Advaxis drugs in Canada

Knight to commercialize Advaxis drugs in Canada

August 26, 2015 by · Leave a Comment 

Tweet Advaxis (NASDAQ:ADXS) has entered into a licensing agreement with Knight Therapeutics (TSX:GUD) to commercialize in Canada Advaxis’ product portfolio, including its three lead drug candidates: axalimogene filolisbac (ADXS-HPV) for human papilloma virus-associated cancers, ADXS-PSA for prostate cancer and ADXS-HER2 for HER2 expressing solid tumors. In connection with the licensing agreement, Knight is purchasing directly […]

Cynapsus to uplist to TSX on Nov. 28

Cynapsus to uplist to TSX on Nov. 28

November 25, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX:CTH) will begin trading on the Toronto Stock Exchange at the opening this Friday, Nov. 28. The shares will continue to trade under the symbol CTH. Trading on the TSX Venture Exchange will end on Friday. The change does not affect trading on the OTCQX International in the U.S. “Uplisting the […]

GeneNews plans private placement, consolidation, U.S. listing

GeneNews plans private placement, consolidation, U.S. listing

December 7, 2012 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) is proposing to complete a private placement of up to 66,666,666 new common shares at a price of 9 cents each for total gross proceeds of up to $6-million. Proceeds will be used to accelerate commercialization of the company’s ColonSentry test in the U.S., development and validation of pipeline products, and general […]

GeneNews partner gets New York okay to market ColonSentry

GeneNews partner gets New York okay to market ColonSentry

February 21, 2012 by · Leave a Comment 

http://www.youtube.com/watch?v=0mzb8_cDcEg’]

Tweet GeneNews (TSX:GEN) announced that Enzo Clinical Labs, a division of Enzo BioChem (NYSE:ENZ), has received approval from New York State’s Department of Health to market ColonSentry, a blood-based test to assess an individual’s current risk for colorectal cancer. Enzo has exclusive rights to market the GeneNews ColonSentry test in the states of New York […]

Isotechnika releases shareholder letter

Isotechnika releases shareholder letter

November 1, 2011 by · Leave a Comment 

Tweet In a letter to shareholders issued today, Isotechnika Pharma (TSX:ISA) CEO Dr. Robert Foster explains the company’s decision to move its voclosporin drug into Phase 3 clinical trials for the prevention of kidney transplant rejection.  He outlines the market opportunity, the scientific rationale and the clinical support for the transplantation indication as well as […]

Isotechnika receives positive scientific advice in Europe for voclosporin

Isotechnika receives positive scientific advice in Europe for voclosporin

October 18, 2011 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) said it has received positive Scientific Advice from the European Medicines Agency for a proposed Phase 3 clinical trial protocol of its drug, voclosporin, after the agency reviewed the study design and endpoints for the proposed clinical study.   This ensures that no major objections regarding the design of the study or […]

Afexa gets promising results in cholesterol management

Afexa gets promising results in cholesterol management

August 18, 2011 by · Leave a Comment 

Tweet Afexa Life Sciences (TSX:FXA), the maker of COLD-FX, has achieved promising results of a pilot clinical study investigating the effects of a new formulation, Dilexaponan, on cholesterol management. The open label and proof of concept study explored the safety and optimum dosing range for Dilexaponan in 39 patients with elevated total cholesterol levels. Dilexaponan is […]

Cangene taps Sedor as CEO

Cangene taps Sedor as CEO

August 17, 2011 by · Leave a Comment 

Tweet Cangene (TSX:CNJ) has named John Sedor as president and CEO, effective Sept. 12, replacing Dr. John Langstaff, who stepped down last January to pursue personal interests. CFO Michael Graham, who has also been serving as interim president and CEO during the board’s search process, will continue in his role as CFO. Mr. Sedor most […]

Paladin eyes Mexico and Brazil for expansion

Paladin eyes Mexico and Brazil for expansion

August 16, 2011 by · Leave a Comment 

Tweet Pharmaceutical distributor Paladin Labs (TSX:PLB) has set its sights on moving into Mexico and Brazil as it continues its strategy of expanding internationally to complement its growth in Canada. “I would like to be in more geographies, and we’re keenly interested in Mexico and Brazil and looking to do something there,” CEO Jonathan Goodman […]

Next Page »

Email Newsletters with Constant Contact
Google+